一分钟看懂
这是一项关于淋巴瘤的I 期研究，登记的药物或干预包括C402-CD19-CAR，当前状态为招募中。登记地点显示中国天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
C402-CD19-CAR · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · 天津
公开的入选条件
- Must meet all the following inclusion criteria:
- 1. Male or female 18-75 years (inclusive);
- 2. Patients can understand this study and capable of providing informed consent;
- 3. Patients with willingness to be in the study and comply with the study visit procedures and other protocol requirements;
- 4. Diagnosed with CD19-positive large B-cell lymphoma (LBCL) based on cytology or histology according to the WHO 2016 standards, including diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), grade 3b follicular lymphoma (FL), transformed diffuse
- 5. For refractory or relapsed large B-cell lymphoma subjects, must have received at least anthracycline-based therapy and rituximab (or other CD20-targeted drugs, excluding CD20-negative cases). If previously treated with R-CHOP or other CD20-targeted therapy,
- 6. According to the 2014 Lugano Treatment Response Assessment Criteria, at least one measurable tumor lesion should be present (lesions can be measured with PET results; lymph node lesions \[long axis LDi \> 15mm\] or extra nodal lesions \[long axis LDi \> 10m
- 7. Expected survival time greater than 12 weeks;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06830031；登记信息更新于 2026-09-11。